Shares of Corbus Pharmaceuticals slid after the company priced its public offering at $13 a share. The stock declined 24% to $12.49 on Friday. Shares are down 22% in the past 12 months.

CStone Pharmaceuticals ( ($HK:2616) ) has provided an update. CStone Pharmaceuticals has announced the appointment of Ms. Fang Xie as an ...

Recursion Pharmaceuticals (RXRX) has grabbed attention following the announcement of its merger with Exscientia, as well as updates on late-stage trial milestones and new regulatory clearances for ...

Exelixis, Inc. (EXEL) is an oncology-focused biotechnology company that primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat ...

These companies are investing heavily into their pipelines and the payoff for long-term investors can be substantial.

An announcement from CStone Pharmaceuticals ( ($HK:2616) ) is now available. CStone Pharmaceuticals announced the composition of its board of ...

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, ...

Investing.com -- PMV Pharmaceuticals Inc (NASDAQ:PMVP) stock rose 2.2% on Friday after the company reported encouraging clinical trial results for its cancer drug rezatapopt, showing responses across ...

Investors are showing growing interest in the rapidly expanding Precision Oncology market, which is expected to witness a compound annual growth rate (CAGR) of 8% between 2025 and 2030, according to ...

According to a filing with the Securities and Exchange Commission dated October 21, 2025, Generali Asset Management reduced ...

The Japanese pharma is licensing up to three next-generation cancer drugs from Innovent Biologics in a deal it believes to be ...